Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metoclopramide + ibuprofen + paracetamol
- Development stage
- Unknown
- Lead developer
- The Kirby Institute
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Metoclopramide + ibuprofen + paracetamol is a multi-drug supportive care regimen developed by the Kirby Institute to manage the side effects of recombinant interleukin-2 (rIL-2) therapy in HIV-1 infected individuals. Evaluated in the TOXIL-2 substudy (NCT00147355) of the Phase 3 ESPRIT trial, the combination consists of metoclopramide (10mg), ibuprofen (200mg), and paracetamol (1g) administered four times daily. Metoclopramide serves as an antiemetic by antagonizing dopamine D2 receptors, while ibuprofen and paracetamol provide anti-inflammatory and analgesic effects by inhibiting cyclooxygenase enzymes. The regimen aims to mitigate gastrointestinal upset and constitutional symptoms (such as fever and malaise) associated with rIL-2, thereby improving patient adherence to and uptake of the immunotherapy cycles.
- Other names
- metoclopramide, ibuprofen, paracetamolTOXIL-2 Arm C regimenTOXIL2 Arm C regimenTOXIL 2 Arm C regimen
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)HTR4 (5-Hydroxytryptamine receptor 4)TRPV1 (Transient receptor potential cation channel subfamily V member 1)HTR3A (5-hydroxytryptamine receptor 3A)PGHS-1 (Prostaglandin G/H Synthase 1)FAAHDRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on metoclopramide + ibuprofen + paracetamol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metoclopramide + ibuprofen + paracetamol.